Genentech's Hemlibra meets in Phase III for hemophilia A

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said subcutaneous Hemlibra emicizumab-kxwh as prophylaxis met the primary endpoint in the Phase III HAVEN 3

Read the full 244 word article

User Sign In